# Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes

> **NCT00145925** · PHASE3 · COMPLETED · sponsor: **The George Institute** · enrollment: 11140 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Perindopril-indapamide
- **DRUG:** Gliclazide MR-based glucose lowering

## Key facts

- **NCT ID:** NCT00145925
- **Lead sponsor:** The George Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 11140 (ACTUAL)
- **Last updated:** 2025-04-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00145925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00145925, "Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT00145925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*